Contagion Editorial Staff

Marcos Pires, PhD, assistant professor at Lehigh University, explains whether or not his team’s strategy to use immunotherapy as a substitute for antibiotics will vary from patient to patient.

Susan Kline, MD, MPH, associate professor of medicine, Division of Infectious Diseases and International Medicine, medical director for Infection Control, lead physician for Antibiotic Stewardship, University of Minnesota, discusses how restricting use of vancomycin impacted the emergence of vancomycin-resistant enterococci.

Megan Luther, PharmD, Advanced Health Services research fellow, Providence Veterans Affairs Medical Center, University of Rhode Island, College of Pharmacy, discusses a meta-analysis that examines the combination therapy of vancomycin and piperacillin/tazobactam causing acute kidney injuries.

Jacob Morton, PharmD, MBA, BCPS, Antibiotic Stewardship Outcomes Post-Doctoral Research Fellow, Providence Veterans Affairs Medical Center, clinical pharmacy research specialist, Wesley Healthcare, discusses his research on 30-day mortality in adults with pneumococcal disease.

Vikas Gupta, PharmD, BCPS, director of Clinical Strategy at Becton Dickinson, explains his team’s unique approach to understanding multidrug-resistant infections.

Rebekah Stewart Schicker, MSN, MPH, APRN, Epidemic Intelligence Service (EIS) Officer at the Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Influenza Division, explains how antiviral flu treatments may be affecting patients in the outpatient setting.

Michael D. Nailor, PharmD, BCPS-AQ ID, clinical associate professor at the University of Connecticut School of Pharmacy, clinical specialist in infectious diseases at Hartford Hospital, and director of Infectious Disease Residency program at Hartford Hospital, discusses the prevalence of skin and soft tissue infections in the United States.

Holly Frost, MD, pediatrics physician scientist at the Marshfield Clinic Research Foundation, in Minocqua, Wisconsin, explains what Powassan virus is.

Susan Kline, MD, MPH, associate professor of medicine, Division of Infectious Diseases and International Medicine, medical director for Infection Control, lead physician for Antibiotic Stewardship, at the University of Minnesota, discusses the growing problem of antibiotic-resistance in hospital-acquired infections.

Daniel Eiras, MD, MPH, hospital epidemiologist at NYU Langone Medical Center, discusses the prevalence of Zika virus infections in New York City.

Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, discusses ceftazidime-avibactam and its uses.

Rebekah Stewart Schicker, MSN, MPH, APRN, Epidemic Intelligence Service (EIS) Officer at the Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Influenza Division, discusses which outpatient populations are at highest risk of influenza-associated complications and the recommended treatments for these individuals.

Rita Olans, DNP, CPNP-PC, APRN-BC, assistant professor at MGH Institute of Health Professions, discusses the importance of incorporating staff nurses in a healthcare setting's antimicrobial stewardship program.

Vikas Gupta, PharmD, BCPS, director of Clinical Strategy at Becton Dickinson, discusses his research on the national prevalence of multidrug-resistant organisms.

Marcos Pires, PhD, assistant professor at Lehigh University, explains the inspiration behind his team’s research in immunotherapy as a new way to fight bacterial infection.

Richard Krieger, MD, chairman of the Infection Control Committee at Chilton Medical Center, and infectious disease physician at ID care, discusses if Lyme disease poses a bigger threat than Zika virus in New Jersey.

Marcos Pires, PhD, assistant professor at Lehigh University, explains the main points behind his research regarding immunotherapy.

Stephen Redd, MD (RADM, USPHS), Director of the Office of Public Health Preparedness and Response (OPHPR) at the Centers for Disease Control and Prevention (CDC), discusses if the public should be concerned by avian influenza.

Stephen Redd, MD (RADM, USPHS), Director of the Office of Public Health Preparedness and Response (OPHPR) at the Centers for Disease Control and Prevention (CDC), explains how to combat anti-vaccine trends.

Stephen Redd, MD (RADM, USPHS), Director of the Office of Public Health Preparedness and Response (OPHPR) at the Centers for Disease Control and Prevention (CDC), discusses the 2016-2017 flu vaccine.

Stephen Redd, MD (RADM, USPHS), Director of the Office of Public Health Preparedness and Response (OPHPR) at the Centers for Disease Control and Prevention (CDC), discusses if the influenza vaccine can be administered to a patient with Zika.

Stephen Redd, MD (RADM, USPHS), Director of the Office of Public Health Preparedness and Response (OPHPR) at the Centers for Disease Control and Prevention (CDC), discusses Zika and sexual transmission.

Stephen Redd, MD (RADM, USPHS), Director of the Office of Public Health Preparedness and Response (OPHPR) at the Centers for Disease Control and Prevention (CDC), discusses what is known about the study that found Zika virus in tears.

The new Centers for Disease Control and Prevention (CDC) recommendations call for a revised dosing schedule.

Stephen Redd, MD (RADM, USPHS), Director of the Office of Public Health Preparedness and Response (OPHPR) at the Centers for Disease Control and Prevention (CDC), discusses if vertical transmission of Zika is cause for concern.

Stephen Redd, MD (RADM, USPHS), Director of the Office of Public Health Preparedness and Response (OPHPR) at the Centers for Disease Control and Prevention (CDC), discusses if southern states will see more Zika infections.

Richard Krieger, MD, chairman of the Infection Control Committee at Chilton Medical Center, and infectious disease physician at ID care, recommends how to reduce the risk of Lyme disease.

Stephen Redd, MD (RADM, USPHS), Director of the Office of Public Health Preparedness and Response (OPHPR) at the Centers for Disease Control and Prevention (CDC), explains what the CDC is doing about Zika.

Richard Krieger, MD, chairman of the Infection Control Committee at Chilton Medical Center, and infectious disease physician at ID care, discusses whether the new Lyme-carrying bacteria, Borrelia mayonii, has different effects than Borrelia burgdorferi.